As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800, as the analyst took over coverage of the stock. Shares have been cut in half over the past six months on worries over Eylea franchise erosion and tariff concerns, notes the analyst, who admits to being “likely early with our Overweight call with a challenging 1Q Eylea print,” but argues that at current levels shares are not only pricing in “a near-disappearance of any Eylea contribution,” as well as “tariff headwinds, zeroing out of the pipeline,” and a haircut to long-term Dupixent estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron: Buy Rating Affirmed Amid Long-term Growth Prospects and Strategic Diversification
- Regeneron price target lowered to $850 from $1,152 at Canaccord
- Regeneron expands manufacturing capacity through new agreement with Fujifilm
- Regeneron assumed at Overweight from Neutral at Cantor Fitzgerald
- Regeneron CRL for Eylea extension not surprising, says Oppenheimer